CDK4 and neoplasm: Goel et al. proved that CDK4/6 inhibitors (abemaciclib, palbociclib, and lapatinib) can increase tumor cell antigen presentation ability, promote CTL-mediated tumor cell clearance, and enhance the immunogenicity of malignant cells by overcoming immune evasion in a mouse breast cancer model (Goel et al., 2017).